Sugi Predict

Sugi Predict / Compounds / SCHEMBL1446212

SCHEMBL1446212

SCHEMBL1446212

CCS(=O)(=O)CNCCOc1cc(F)cc(NC(=O)Nc2ccc(C)nc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KCNQ3 O43525 1/20 0.39
▸ KCNQ2 O43526 1/20 0.39
▸ MAPK10 P53779 3/20 0.38
▸ MAPK8 P45983 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ HRH3 Q9Y5N1 3/20 0.37
▸ PABPC1 P11940 1/20 0.37
▸ PAX8 Q06710 1/20 0.37
▸ DDX3X O00571 1/20 0.37
▸ CASP3 P42574 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1446027 0.90 MEN1 (0.49) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1445986 0.89 CYP1A2 (0.49) MEN1KMT2AMAPTLMNAHTT
SCHEMBL1446069 0.89 CYP1A2 (0.42) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1447096 0.84 NPSR1 (0.38) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1445961 0.84 NPSR1 (0.38) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL398555 0.83 NPSR1 (0.41) MEN1KMT2ANPSR1SMN1; SMN2KCNQ3
SCHEMBL1446211 0.80 HRH3 (0.45) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1446068 0.78 HRH3 (0.45) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1446415 0.78 HRH3 (0.43) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL1447101 0.78 MAPT (0.47) MEN1KMT2AMAPTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910743-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-03-22 — — US claimed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 — — US claimed
US-20070066626-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2007-03-22 — — US claimed
US-7910743-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-03-22 — — US disclosed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 — — US disclosed
US-7538223-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2009-05-26 — — US disclosed
US-20070066626-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2007-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324511-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885MAPT 663/4885
US-20070066626-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885MAPT 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.